CLINICAL BENEFIT OF LENALIDOMIDE TREATMENT FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME WITH DEL(5Q) BEFORE TRANSFUSION DEPENDENCE

被引：0

作者：

Oliva, E. ^{[1
]}

Lauseker, M. ^{[2
]}

Spiriti, M. A. Aloe ^{[3
]}

Poloni, A. ^{[4
]}

Cortelezzi, A. ^{[5
]}

Palumbo, G. ^{[6
]}

Balleari, E. ^{[7
]}

Sanpaolo, G. ^{[8
]}

Volpe, A. ^{[9
]}

Ricco, A. ^{[10
]}

Ronco, F. ^{[1
]}

Alati, C. ^{[1
]}

Santacaterina, I. ^{[1
]}

Kuendgen, A. ^{[11
]}

Germing, U. ^{[11
]}

Latagliata, R. ^{[12
]}

机构：

[1] Azienda Osped BMM, Reggio Di Calabria, Italy

[2] Univ Munich, Inst Med Informat Sci Biometry & Epidemiol, Munich, Germany

[3] Univ Roma La Sapienza, Dipartimento Med Clin & Mol, I-00185 Rome, Italy

[4] Univ Politecn Marche, Ancona, Italy

[5] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[6] Azienda Osped Univ Policlin Vittorio Emanuele, Catania, Italy

[7] Osped San Martino Genova, Hematol Unit, Genoa, Italy

[8] Osped Casa Sollievo della Sofferenza, Hematol Div, San Giovanni Rotondo, Italy

[9] Azienda Osped San G Moscati, Avellino, Italy

[10] Univ Bari, Bari, Italy

[11] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany

[12] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S1331

引用

页码：517 / 517

页数：1

共 50 条

[41] RUNX1 LOSS OF FUNCTION DRIVES RESISTANCE TO LENALIDOMIDE IN DEL(5Q) MYELODYSPLASTIC SYNDROME PATIENTS
Martinez-Hoyer, S.
Mo, A.
Docking, R.
Li, J.
Chan, S.
Umlandt, P.
Fuller, M.
Jadersten, M.
Hellstrom-Lindberg, E.
Platzbecker, U.
Parker, J.
Karsan, A.
LEUKEMIA RESEARCH, 2017, 55 : S43 - S44
[42] A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO.
Toma, Andrea
Chevret, Sylvie
Kosmider, Olivier
Delaunay, Jacques
Stamatoullas, Aspasia
Rose, Christian
Beyne-Rauzy, Odile
Banos, Anne
Guercy-Bresler, Agnes
Jourdan, Eric
Sardnal, Veronique
Caillot, Denis
Laribi, Kamel
De Renzis, Benoit
Bordessoule, Dominique
Slama, Borhane
Sanhes, Laurence
Fontenay, Michaela
Fenaux, Pierre
Dreyfus, Francois
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[43] Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion
Yahiya Y. Syed
Lesley J. Scott
Drugs, 2013, 73 : 1183 - 1196
[44] Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial
Garcia-Manero, Guillermo
Almeida, Antonio
Fenaux, Pierre
Gattermann, Norbert
Giagounidis, Aristoteles
Goldberg, Stuart L.
Ozawa, Keiya
Weaver, Jerry
Santini, Valeria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 213 - +
[45] Response and progression rate of patients with primary MDS and isolated del(5q), IPSS low/int1 under treatment with lenalidomide
Germing, U.
Giagounidis, A.
Buesche, G.
Platzbecker, U.
Goetze, K.
Nolte, F.
Schlenk, R. F.
Letsch, A.
Ganser, A.
Luebbert, M.
Bug, G.
Schafhausen, P.
Schemenau, J.
Haase, D.
LEUKEMIA RESEARCH, 2013, 37 : S163 - S163
[46] Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion
Syed, Yahiya Y.
Scott, Lesley J.
DRUGS, 2013, 73 (11) : 1183 - 1196
[47] Short Telomeres Before Lenalidomide Treatment Predict Leukemic Progression In Patients with Myelodysplastic Syndrome and Deletion 5q
Gohring, Gudrun
Lange, Kathrin
Hofmann, Winfried
Nielsen, Kirsten Vang
Hellstrom-Lindberg, Eva
Roy, Lydia
Morgan, Michael
Kreipe, Hans
Buesche, Guntram
Giagounidis, Aristoteles
Schlegelberger, Brigitte
BLOOD, 2010, 116 (21) : 18 - 18
[48] Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study
Crisa, Elena
Mora, Elvira
Germing, Ulrich
Bally, Cecile
Campelo, Maria Diez
Myllymaki, Mikko
Jadersten, Martin
Komrokji, Rami
Platzbecker, Uwe
Haase, Detlef
Hofmann, Wolf-Karsten
Al Ali, Najla H.
Barraco, Daniela
Bargay, Juan Jose
Bernal, Teresa
Cadenas, Felix Lopez
Calvisi, Anna
Capodanno, Isabella
Cerrano, Marco
Ciancia, Rosanna
Crugnola, Monica
Kundgen, Andrea
Finelli, Carlo
Fozza, Claudio
Frairia, Chiara
Freja, Ebeling
Ganster, Christina
Kubasch, Anne Sophie
Jimenez, Maria Jose
Latagliata, Roberto
Mohedo, Francisca Hernandez
Molero, Antonieta
Pampliega, Miriam Vara
Perez, Clara Aparicio
Pietrantuono, Giuseppe
Poloni, Antonella
Pomares, Helena
Recasens, Valle
Rufer, Axel
Signori, Alessio
Hellstrom-Lindberg, Eva
Fenaux, Pierre
Sanz, Guillermo
Santini, Valeria
LEUKEMIA, 2024, 38 (10) : 2259 - 2265
[49] Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide
Beier, Fabian
Kharabi Masouleh, Behzad
Buesche, Guntram
Ventura Ferreira, Monica S.
Schneider, Rebekka K.
Ziegler, Patrick
Wilop, Stefan
Vankann, Lucia
Gattermann, Norbert
Platzbecker, Uwe
Giagounidis, Aristoteles
Goetze, Katharina S.
Nolte, Florian
Hofmann, Wolf-Karsten
Haase, Detlef
Kreipe, Hans
Panse, Jens
Blasco, Maria A.
Germing, Ulrich
Bruemmendorf, Tim H.
LEUKEMIA RESEARCH, 2015, 39 (11) : 1292 - 1298
[50] Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome with Isolated Del(5q) with Lenalidomide, Bortezomib, and Dexamethasone
Washington, Nyomi
Shippey, Eugen A., III
Osswald, Michael B.
BLOOD, 2020, 136

← 1 2 3 4 5 →